Overview: Allergy Eczema Vegetarian Panel
Introduction: The Allergy Eczema Vegetarian Panel is a diagnostic tool designed to screen for eczema-related food allergens in vegetarian diets using serum samples. In India, atopic dermatitis (eczema) affects 3-7 percent of children and 0.98-9.2 percent overall, with high sensitization to common vegetarian foods like wheat, soy, lentils, and legumes due to staple diet. Clinical food allergy is low (0.14-1.2 percent confirmed), but sensitization often leads to unnecessary restrictions and nutritional concerns. Presents with intense itching, red rash, dry skin, and flares after meals. High morbidity from underdiagnosis or over-restriction in pediatric and adult patients, especially in vegetarian-majority households. Per immunology practices (ICMR aligned), the test employs immunoassay for detailed parameter analysis over 1-2 days with high sensitivity/specificity, valuable for identifying potential food triggers in eczema cases. This diagnostic falls under allergy screening and targets individuals with suspected food-related eczema, addressing accurate detection to guide targeted dietary advice and prevent malnutrition. With morbidity elevated due to underdiagnosis in low-SES groups, the test supports public health efforts by enabling precise identification, facilitating management, and reducing unnecessary eliminations. Its serum-based approach ensures reliable detection.
Other Names: Eczema Veg Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Expanded with specific IgE testing; in India, relevance with vegetarian diet prevalence.
Purpose: The test screens for 9 parameters including wheat IgE to guide eczema assessment, identify food triggers, inform dietary management.
Test Parameters: 1. Total IgE, 2. Wheat IgE, 3. Soy IgE, 4. Peanut IgE, 5. Lentil IgE, 6. Chickpea IgE, 7. Potato IgE, 8. Tomato IgE, 9. Eggplant IgE.
Pretest Condition: No fasting required; patients should report eczema flares after vegetarian foods.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on eczema severity, diet (vegetarian staples), symptom timing after meals, family allergy history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated eczema or unnecessary diet restrictions, benefits of early detection, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or dietary variations can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible food triggers, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if flares persist.
Specialist Consultation: Dermatologists or allergists should be consulted for case management, dietary planning, and coordination with nutrition programs.
Additional Supporting Tests: Patch testing or elimination diet trial for confirmation.
Test Limitations: The test may produce false negatives in non-IgE mediated eczema or false positives in sensitization without clinical flare, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: Indian Journal of Dermatology 2024, Atopic Dermatitis Studies India 2023.
